Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.36 |
| ▸ | FAP | Q12884 | 2/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13163969 | 0.87 | DPP4 (0.42) | DPP4DPP7RIPK1ALDH1A1GRM5 | |
| SCHEMBL21187742 | 0.86 | DPP4 (0.40) | DPP4DPP7KDM4EALDH1A1GAA | |
| SCHEMBL20221436 | 0.83 | DPP4 (0.46) | DPP4DPP7NAMPTDPP8DPP9 | |
| SCHEMBL28149214 | 0.81 | DPP4 (0.47) | DPP4DPP7NAMPTDPP8DPP9 | |
| SCHEMBL24159169 | 0.80 | — | — | |
| SCHEMBL4830838 | 0.79 | DPP4 (0.46) | DPP4DPP7NAMPTDPP8DPP9 | |
| SCHEMBL15701184 | 0.79 | DPP4 (0.46) | DPP4DPP7NAMPTDPP8DPP9 | |
| SCHEMBL31722536 | 0.78 | DPP4 (0.39) | DPP4DPP7KDM4EALDH1A1GAA | |
| SCHEMBL14655434 | 0.78 | DPP4 (0.43) | DPP4DPP7NAMPTDPP8DPP9 | |
| SCHEMBL3116395 | 0.77 | DPP4 (0.45) | DPP4DPP7NAMPTDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20220298107-A1 | SUBSTITUTED UREA DIHYDROOROTATE DEHYDROGENASE INHIBITORS | JANSSEN BIOTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114286813-A | Substituted urea dihydroorotate dehydrogenase inhibitors | 詹森生物科技公司 | 2022-04-05 | — | — | CN | disclosed |
| WO-2020099882-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2020-05-22 | — | — | WO | disclosed |
| WO-2019149658-A1 | PYRAZOLE- AND INDAZOLE-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
| WO-2015130795-A1 | AMIDE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015027021-A1 | IMIDE AND ACYLUREA DERIVATIVES AS MODULATORS OF THE GLUCOCORTICOID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-02-26 | — | — | WO | disclosed |
| WO-2012083117-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298107-A1 | SUBSTITUTED UREA DIHYDROOROTATE DEHYDROGENASE INHIBITORS | DHODH, DPYD, UGDH | DPP4 2302/4885DPP7 2425/4885NAMPT 419/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | DPP4 67/4885DPP7 102/4885NAMPT 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.